Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Anemia

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 67 articles: HTML format

Single Articles

March 2023
1. BURTSCHER M
   Oxygen Delivery in the Treatment of Anemia.
   N Engl J Med. 2023;388:e38.
   PubMed    
   
   
   
2. LEE AI, Heidari P, Fenves AZ, Bardia A, et al
   Case 8-2023: A 71-Year-Old Woman with Refractory Hemolytic Anemia.
   N Engl J Med. 2023;388:1032-1041.
   PubMed    
   
   
   December 2022
3. MC CAUSLAND FR, Singh AK, Claggett BL, Carroll K, et al
   Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply.
   N Engl J Med. 2022;387:2482-2485.
   PubMed    
   
   
   
4. HUANG C, He Y, Li Y
   Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
   N Engl J Med. 2022;387:2482.
   PubMed    
   
   
   
5. ROJAS-RIVERA J, Carriazo S, Ortiz A
   Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease.
   N Engl J Med. 2022;387:2481-2482.
   PubMed    
   
   
   
6. BUNN HF
   Oxygen Delivery in the Treatment of Anemia.
   N Engl J Med. 2022;387:2362-2365.
   PubMed    
   
   
   September 2022
7. DEBAUN M, Heeney M, Jackson T, Longo D, et al
   Sickle Cell Disease and Gene Therapy - Patient and Physician Perspectives.
   N Engl J Med. 2022;387:e28.
   PubMed    
   
   
   August 2022
8. ZHOU AE, Travassos MA
   Bringing Sickle-Cell Treatments to Children in Sub-Saharan Africa.
   N Engl J Med. 2022;387:488-491.
   PubMed    
   
   
   July 2022
9. WU YW, Comstock BA, Gonzalez FF, Mayock DE, et al
   Trial of Erythropoietin for Hypoxic-Ischemic Encephalopathy in Newborns.
   N Engl J Med. 2022;387:148-159.
   PubMed     Abstract available
   
   
   
10. NOTARO R, Luzzatto L
    Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition.
    N Engl J Med. 2022;387:160-166.
    PubMed    
    
    
    June 2022
11. AL-SAMKARI H, Beynon V, van Beers EJ
    Mitapivat versus Placebo for Pyruvate Kinase Deficiency. Reply.
    N Engl J Med. 2022;386:2539.
    PubMed    
    
    
    
12. SHAH AJ, Schwartz JD, Segovia JC
    Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
    N Engl J Med. 2022;386:2538-2539.
    PubMed    
    
    
    April 2022
13. DI MEGLIO L, Scott A
    Iris Atrophy in Sickle Cell Disease.
    N Engl J Med. 2022;386:1646.
    PubMed    
    
    
    
14. AL-SAMKARI H, Galacteros F, Glenthoj A, Rothman JA, et al
    Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
    N Engl J Med. 2022;386:1432-1442.
    PubMed     Abstract available
    
    
    February 2022
15. STEINBERG MH
    Fetal-like Hemoglobin in Sickle Cell Anemia.
    N Engl J Med. 2022;386:689-691.
    PubMed    
    
    
    
16. KANTER J, Walters MC, Krishnamurti L, Mapara MY, et al
    Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
    N Engl J Med. 2022;386:617-628.
    PubMed     Abstract available
    
    
    
17. PAYEN E
    Efficacy and Safety of Gene Therapy for beta-Thalassemia.
    N Engl J Med. 2022;386:488-490.
    PubMed    
    
    
    
18. LOCATELLI F, Thompson AA, Kwiatkowski JL, Porter JB, et al
    Betibeglogene Autotemcel Gene Therapy for Non-beta(0)/beta(0) Genotype beta-Thalassemia.
    N Engl J Med. 2022;386:415-427.
    PubMed     Abstract available
    
    
    January 2022
19. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    
    
    
    
20. SCHEINBERG P
    A New Standard Immunosuppression Regimen in Severe Aplastic Anemia.
    N Engl J Med. 2022;386:89-90.
    PubMed    
    
    
    
21. PEFFAULT DE LATOUR R, Kulasekararaj A, Iacobelli S, Terwel SR, et al
    Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia.
    N Engl J Med. 2022;386:11-23.
    PubMed     Abstract available
    
    
    December 2021
22. WILLETT LL, Bromberg GK, Chung R, Leaf RK, et al
    Case 38-2021: A 76-Year-Old Woman with Abdominal Pain, Weight Loss, and Memory Impairment.
    N Engl J Med. 2021;385:2378-2388.
    PubMed    
    
    
    
23. GOYAL S, Tisdale J, Schmidt M, Kanter J, et al
    Acute Myeloid Leukemia Case after Gene Therapy for Sickle Cell Disease.
    N Engl J Med. 2021 Dec 12. doi: 10.1056/NEJMoa2109167.
    PubMed     Abstract available
    
    
    
24. PASRICHA SR, Hamadani JD, Biggs BA
    Benefits and Risks of Iron Interventions in Infants in Bangladesh. Reply.
    N Engl J Med. 2021;385:2199.
    PubMed    
    
    
    
25. TERADA R, Sato T
    Benefits and Risks of Iron Interventions in Infants in Bangladesh.
    N Engl J Med. 2021;385:2198-2199.
    PubMed    
    
    
    November 2021
26. JONASCH E, Donskov F, Iliopoulos O, Rathmell WK, et al
    Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
    N Engl J Med. 2021;385:2036-2046.
    PubMed     Abstract available
    
    
    
27. SINGH AK, Carroll K, McMurray JJV, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113380.
    PubMed     Abstract available
    
    
    
28. PARFREY P
    Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Anemia in CKD.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMe2117100.
    PubMed    
    
    
    
29. SINGH AK, Carroll K, Perkovic V, Solomon S, et al
    Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    N Engl J Med. 2021 Nov 5. doi: 10.1056/NEJMoa2113379.
    PubMed     Abstract available
    
    
    October 2021
30. HILLMEN P, Risitano AM, Peffault de Latour R
    Pegcetacoplan versus Eculizumab in PNH. Reply.
    N Engl J Med. 2021;385:1725-1726.
    PubMed    
    
    
    
31. GURNARI C, Pagliuca S, Maciejewski JP
    Pegcetacoplan versus Eculizumab in PNH.
    N Engl J Med. 2021;385:1725.
    PubMed    
    
    
    
32. KULASEKARARAJ AG, Gandhi S, Brodsky RA
    Pegcetacoplan versus Eculizumab in PNH.
    N Engl J Med. 2021;385:1724-1725.
    PubMed    
    
    
    
33. UEDA Y, Takamori H, Nishimura JI
    Pegcetacoplan versus Eculizumab in PNH.
    N Engl J Med. 2021;385:1723-1724.
    PubMed    
    
    
    
34. CHERTOW GM, Eckardt KU
    Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease. Reply.
    N Engl J Med. 2021;385:e56.
    PubMed    
    
    
    
35. BUNN HF
    Vadadustat for Anemia in Patients with Dialysis-Dependent or Non-Dialysis-Dependent Chronic Kidney Disease.
    N Engl J Med. 2021;385:e56.
    PubMed    
    
    
    
36. HOCK H, Kelly HR, Meyerowitz EA, Frigault MJ, et al
    Case 31-2021: A 21-Year-Old Man with Sore Throat, Epistaxis, and Oropharyngeal Petechiae.
    N Engl J Med. 2021;385:1511-1520.
    PubMed    
    
    
    
37. BERENTSEN S, Barcellini W
    Autoimmune Hemolytic Anemias.
    N Engl J Med. 2021;385:1407-1419.
    PubMed    
    
    
    September 2021
38. PASRICHA SR, Hasan MI, Braat S, Larson LM, et al
    Benefits and Risks of Iron Interventions in Infants in Rural Bangladesh.
    N Engl J Med. 2021;385:982-995.
    PubMed     Abstract available
    
    
    
39. PICHAN C, Dhaliwal G, Cusick A, Saint S, et al
    Inadequate Support.
    N Engl J Med. 2021;385:938-944.
    PubMed    
    
    
    August 2021
40. GURNARI C, Rogers HJ
    Copper Deficiency.
    N Engl J Med. 2021;385:640.
    PubMed    
    
    
    July 2021
41. AVELAR RODRIGUEZ D, Orkin J
    An Icteric Tongue.
    N Engl J Med. 2021;385:e16.
    PubMed    
    
    
    
42. PISCHEL L, Geirsson A, Magaldi J, Martinello RA, et al
    A Brewing Back Pain.
    N Engl J Med. 2021;385:66-72.
    PubMed    
    
    
    June 2021
43. FRANGOUL H, Ho TW, Corbacioglu S
    CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. Reply.
    N Engl J Med. 2021;384:e91.
    PubMed    
    
    
    
44. MEHTA J
    CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia.
    N Engl J Med. 2021;384:e91.
    PubMed    
    
    
    
45. MEISEL R
    CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia.
    N Engl J Med. 2021;384:e91.
    PubMed    
    
    
    
46. TAHER AT, Musallam KM, Cappellini MD
    beta-Thalassemias. Reply.
    N Engl J Med. 2021;384:2166.
    PubMed    
    
    
    
47. GEORGALAS I, Petrou P, Kanakis M
    beta-Thalassemias.
    N Engl J Med. 2021;384:2165-2166.
    PubMed    
    
    
    
48. THONG MK, Ngim CF
    beta-Thalassemias.
    N Engl J Med. 2021;384:2165.
    PubMed    
    
    
    May 2021
49. MUSTJOKI S, Young NS
    Somatic Mutations in "Benign" Disease.
    N Engl J Med. 2021;384:2039-2052.
    PubMed    
    
    
    
50. GIBBONS MD, Mendoza DP, Waheed A, Barshak MB, et al
    Case 14-2021: A 64-Year-Old Woman with Fever and Pancytopenia.
    N Engl J Med. 2021;384:1849-1857.
    PubMed    
    
    
    April 2021
51. LEVIN A
    Therapy for Anemia in Chronic Kidney Disease - New Interventions and New Questions.
    N Engl J Med. 2021;384:1657-1658.
    PubMed    
    
    
    
52. ECKARDT KU, Agarwal R, Aswad A, Awad A, et al
    Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    N Engl J Med. 2021;384:1601-1612.
    PubMed     Abstract available
    
    
    
53. CHERTOW GM, Pergola PE, Farag YMK, Agarwal R, et al
    Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    N Engl J Med. 2021;384:1589-1600.
    PubMed     Abstract available
    
    
    
54. ROTH A, Barcellini W, D'Sa S, Miyakawa Y, et al
    Sutimlimab in Cold Agglutinin Disease.
    N Engl J Med. 2021;384:1323-1334.
    PubMed     Abstract available
    
    
    March 2021
55. HILLMEN P, Szer J, Weitz I, Roth A, et al
    Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
    N Engl J Med. 2021;384:1028-1037.
    PubMed     Abstract available
    
    
    
56. OGUNWOLE SM
    Without Sanctuary.
    N Engl J Med. 2021;384:791-793.
    PubMed    
    
    
    February 2021
57. MENON BS, Teh KH
    Gum Hypertrophy from Cyclosporine.
    N Engl J Med. 2021;384:744.
    PubMed    
    
    
    
58. TAHER AT, Musallam KM, Cappellini MD
    beta-Thalassemias.
    N Engl J Med. 2021;384:727-743.
    PubMed    
    
    
    January 2021
59. MALECH HL
    Treatment by CRISPR-Cas9 Gene Editing - A Proof of Principle.
    N Engl J Med. 2021;384:286-287.
    PubMed    
    
    
    
60. WALTERS MC
    Induction of Fetal Hemoglobin by Gene Therapy.
    N Engl J Med. 2021;384:284-285.
    PubMed    
    
    
    
61. ESRICK EB, Lehmann LE, Biffi A, Achebe M, et al
    Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease.
    N Engl J Med. 2021;384:205-215.
    PubMed     Abstract available
    
    
    
62. FRANGOUL H, Altshuler D, Cappellini MD, Chen YS, et al
    CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia.
    N Engl J Med. 2021;384:252-260.
    PubMed     Abstract available
    
    
    December 2020
63. KIRPALANI H, Bell EF, Hintz SR, Tan S, et al
    Higher or Lower Hemoglobin Transfusion Thresholds for Preterm Infants.
    N Engl J Med. 2020;383:2639-2651.
    PubMed     Abstract available
    
    
    
64. MENSAH F, Pilichowska M
    Hemophagocytosis of Sickle Cells.
    N Engl J Med. 2020;383:2571.
    PubMed    
    
    
    
65. KWAMBAI TK, Dhabangi A, Idro R, Opoka R, et al
    Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.
    N Engl J Med. 2020;383:2242-2254.
    PubMed     Abstract available
    
    
    November 2020
66. MALHOTRA R, Namasivayam M, Ghoshhajra BB, Passeri JJ, et al
    Case 36-2020: A 72-Year-Old Woman with Dark Urine and Weakness.
    N Engl J Med. 2020;383:2066-2076.
    PubMed    
    
    
    
67. POWER-HAYS A, McGann PT
    When Actions Speak Louder Than Words - Racism and Sickle Cell Disease.
    N Engl J Med. 2020;383:1902-1903.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Anemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: